All In Biotech

Drug Trial Radar · NCT05468554

Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Nov 1, 2022

Primary completion

Jan 31, 2028

Study completion Apr 30, 2028

Sponsor

Lead sponsor
Medical University of BialystokAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medical Research Agency, Poland; Holy Cross Cancer Center in Kielce; University Clinical Hospital in Poznań; Maria Skłodowska-Curie National Research Institute of Oncology; University Clinical Hospital in Białystok
First posted
Jul 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is aimed to investigate the metformin effect on the fertility of women treated with 131 I for thyroid cancer

Conditions

  • Thyroid Cancer

Interventions

  • metforminDrug

    Metformin will be used 3 times a day (3x500mg), starting in the first week with 1x1 tablet (1x500 mg for breakfast), in the second week, 2x1 tablet (500 mg for breakfast and 500 mg for dinner), from the 3rd week 3x1 tablet. (3x500mg with main meals). A gradual escalation of the dose is planned to the point of developing drug intolerance or toxicity that is unacceptable to the patient.

  • Radioactive iodine (I-131)Radiation

    Patients qualified to receive 131I treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in AMH, Inhibin B and FSH levels due to the action of metforminTime frame: 4 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Department of Endocrinology, Diabetology and Internal Medicine, Medical Univeristy of Bialystok

    Bialystok, Poland · Recruiting

  • Holy Cross Cancer Center

    Kielce, Świetokrzystie, Poland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.